ABBV has pulled back one percent on the day to close at $251.64, but that modest retreat comes after a stunning 7% weekly gain — and the underlying positioning still tells a bullish story heading into July 27 earnings.
Options traders are the clearest signal that sentiment has turned. The put/call ratio has dropped to 0.756, more than one standard deviation below its 20-day average of 0.835 — the most call-heavy tilt the ratio has produced in months. Compare that to early June, when the PCR was running consistently above 0.93. The shift is not subtle. Call demand has been building steadily since the Apogee acquisition digest cleared, and the 52-week PCR low of 0.623 now looks like the direction of travel rather than a floor. The short interest picture corroborates this: bears have trimmed for a second straight week, with SI % FF falling to 1.31% — the lightest short position in over a month. Borrow availability is effectively unlimited at this size, with over a billion shares available against roughly 23 million short. Borrowing costs did jump 47% on the week to 0.58%, but in absolute terms that remains trivially low. There is no squeeze pressure and no sign that new short conviction is building.
The Street is broadly constructive, though not uniformly so. Piper Sandler reiterated Overweight with a $298 target last week, and Canaccord raised its target to $273 from $265 on the same day — both citing pipeline confidence. The consensus sits at "hold" with a mean target of $256, barely above Tuesday's close, which means the bull case relies entirely on execution rather than multiple expansion. Morgan Stanley raised to $278 post-Q1 results; Evercore has $235, now below the current price. The forward earnings yield factor ranks in the 99th percentile for 12-month EPS growth — the single strongest factor score in the dataset — while the dividend score ranks 98th. EPS surprise, however, ranks in just the 9th percentile, a reminder that AbbVie's earnings history has been uneven on the beat-and-raise dimension.
The bull and bear cases are well-defined ahead of the July print. Bulls point to Skyrizi, Rinvoq, and the Apogee pipeline — particularly zumilokibart, which analysts see as a potential blockbuster in atopic dermatitis — plus the company's track record of combination-therapy revenue diversification. Bears flag execution risk in immunology and oncology, the aesthetics business (roughly 8% of sales) facing macro headwinds, and integration risk from both Cerevel and ImmunoGen alongside the fresh Apogee deal. The PE multiple at 14.3x and EV/EBITDA at 12.8x are not stretched by large-cap pharma standards, but the price-to-book at 117x reflects just how capital-light the franchise is being priced.
Among close peers, HALO led the week with a 12.4% gain, INCY added 8.6%, and VRTX rose 6% — suggesting the move in ABBV was part of a broader biotech/pharma lift rather than company-specific repricing alone. AMGN gained 4.4%, while GILD lagged at just 1%.
With Q2 results four weeks out on July 27, the question that will matter most is whether Skyrizi and Rinvoq growth rates are holding above the mid-teens and whether the Apogee integration timeline is firming up — not whether the stock can hold $250.
See the live data behind this article on ORTEX.
Open ABBV on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
